|The full article is available to subscribers||Subscriber Login|
The FDA has approved use of Exablate Neuro (Insightec) for unilateral thalamotomy to treat medication-refractory essential tremor in patients ≥22 years old. Exablate Neuro uses magnetic resonance-guided focused ultrasound (MRgFUS) to create lesions in the ventral intermediate nucleus of the thalamus. MRgFUS is also approved in the US for treatment of uterine fibroids and for pain palliation of bone metastases.
TREATMENT OF ESSENTIAL TREMOR — Essential tremor is a common neurological disorder that causes involuntary and rhythmic shaking, especially of the hand, head, neck, and voice. The tremor is not life threatening, but it can be distressing and make performance of everyday activities difficult. The most effective drugs used to treat essential tremor are the beta blocker propranolol (Inderal, and others) and (off-label) the anticonvulsant primidone (Mysoline, and generics); they... more
- TA Zesiewicz et al. Practice parameter: therapies for essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2005; 64:2008.
- TA Zesiewicz et al. Evidence-based guideline update: treatment of essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2011; 77:1752.
- P Ghanouni et al. Transcranial MRI-guided focused ultrasound: a review of the technologic and neurologic applications. AJR Am J Roentgenol 2015; 205:150.
- Exablate Model 4000 Type 1. Information for prescribers. Available at: www.accessdata.fda.gov. Accessed March 16, 2017.
- WJ Elias. A randomized trial of focused ultrasound thalamotomy for essential tremor. N Engl J Med 2016; 375:730.
- WS Chang et al. Factors associated with successful magnetic resonance-guided focused ultrasound treatment: efficiency of acoustic energy delivery through the skull. J Neurosurg 2016; 124:411.
- FDA. Summary of safety and effectiveness data (SSED). Available at www.accessdata.fda.gov. Accessed March 16, 2017.